Precision BioSciences (DTIL) Projected to Post Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $5.00 million for the quarter.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by ($1.11). The company had revenue of $3.47 million during the quarter, compared to analysts' expectations of $4.28 million. Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Performance

DTIL stock traded up $0.01 during trading on Friday, hitting $5.16. 96,089 shares of the company traded hands, compared to its average volume of 182,599. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $13.44. The company has a market cap of $54.44 million, a PE ratio of 86.01 and a beta of 1.55. The stock's 50-day simple moving average is $5.03 and its 200 day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday, March 28th. BMO Capital Markets upgraded Precision BioSciences from a "market perform" rating to an "outperform" rating and set a $34.00 price objective for the company in a research report on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.